Global leader in women’s health partners with medical streaming platform, Mediflix, to provide first-of-its-kind awareness and education tool highlighting reconstructive options for breast cancer patients

In conjunction with ongoing Breast Cancer Awareness Month efforts, Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, unveiled Carolina, a narrative documentary-style film about the breast cancer journey from diagnosis to reconstruction, developed in collaboration with Mediflix and Moonlight Productions.

Released on the Mediflix streaming platform timed to Breast Reconstruction Awareness Day (Oct. 20), Carolina follows a fictional patient through her cancer diagnosis and treatment, and features testimonials from real breast cancer survivors and clinicians about the physical and emotional experiences that women overcome throughout their breast cancer battle. This documentary provides a platform to help recently diagnosed breast cancer patients better understand the latest minimally invasive options available that treat breast cancer and address the real concern of physical appearance. Knowing options at the earliest stage of diagnosis helps inform decision making and increases confidence.

“Enabling healthier lives, everywhere, every day, to support better health outcomes is engrained in our mission, and this first-of-its-kind partnership with Mediflix represents an exciting new way for us to provide value to viewers and breast cancer patients alike,” said Jennifer Meade, Hologic's division president, Breast & Skeletal Health Solutions. “Women are faced with so many options and opinions when it comes to breast cancer treatment, which can be overwhelming and emotionally taxing. This film helps educate women about their options for breast cancer surgery and breast reconstruction, reinforcing the fact that they don’t need to sacrifice their confidence to live a healthy life.”

Post-surgery appearance is one concern several survivors share in the film, as many associate breast cancer surgeries with scarring and indentations where the cancer was removed. More recent technological advancements in breast health have resulted in options such as Reconstructive Lumpectomy™ breast cancer surgery, a 2-in-1 procedure that removes the cancerous mass and uses plastic surgery techniques to reconstruct the breast using Hologic’s BioZorb® 3D implantable marker.

“Our goal as breast cancer surgeons is to not only remove the cancer, but if we have to remove a cancer that’s large enough to potentially cause a deformity, to construct the breast to its natural shape,” said Breast Oncologist, Linda Han, M.D., at Parkview Health in Indiana. “Sometimes we don’t have enough of the surrounding breast tissue to fill in that volume or void, and we’re able to supplement that by using this open bioabsorbable matrix that acts as a support for the surrounding tissue.”

BioZorb marker helps maintain breast shape through its spiral framework that is embedded with six permanent, titanium clips designed to precisely mark the surgical excision site and has been shown in a case series to yield good to excellent cosmetic outcomes for at least 2 years post-surgery.¹

“We’re proud to present Carolina on the Mediflix platform,” said Sharon Cammisa, CCO, Mediflix. “Our goal is to inspire, inform and empower our audience, and Carolina checks all those boxes.”

Learn more about Reconstructive Lumpectomy breast cancer surgery at www.ShapeHerFuture.com and watch the 20-minute film on the Mediflix platform, at www.mediflix.com/video/breastcancer.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic, The Science of Sure, BioZorb and Reconstructive Lumpectomy are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.

SOURCE: Hologic, Inc.

¹ N = 20. Kaufman CS, et al. Long Term Value of 3-D Bioabsorbable Tissue Marker on Radiation Planning & Targeting, Cosmesis and Follow-up Imaging. Poster presented at the American Society of Breast Surgeons 17th Annual Meeting, April 27 – 30, 2017

View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005212/en/

Hologic Debuts Documentary-style Film Highlighting One Woman's Breast Cancer Journey Timed to Breast Reconstruction Awareness Day